Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzymatic Asymmetric Reduction. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN110387359A enables high-purity statin intermediate production via engineered carbonyl reductase mutants ensuring supply chain stability.
Patent CN112481226A discloses solvent-tolerant ADH mutants enabling 99.9% conversion for chiral diaryl alcohols, offering a green alternative to costly chemical synthesis.
Patent CN111433357B reveals high-ee enzymatic reduction for chiral alcohols, offering cost-effective and scalable supply chain solutions for pharmaceutical intermediates.
Patent CN112481226B details solvent-tolerant ADH mutants for scalable production of chiral alcohols, offering significant cost reduction and supply chain reliability for pharma intermediates.
Patent CN114686451A discloses amine dehydrogenase mutants for high-yield production. Offers cost reduction in pharma intermediate manufacturing with >99% ee.
Patent CN114350631B reveals a novel NADH-dependent enzyme mutant for L-glufosinate synthesis, offering significant cost reduction and supply chain stability for agrochemical manufacturing.
Patent CN102605011B details a novel KRED102-catalyzed route for statin intermediates, offering high-purity chiral building blocks with simplified aqueous processing and reduced manufacturing costs.
Patent CN109837317B details a novel enzymatic method for synthesizing high-purity chiral alcohols, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN111454918A details a novel OYE3-Mut mutant for >99% ee (R)-citronellal, offering cost-effective biocatalytic solutions for flavor and pharma intermediates.
Novel LsCR mutant enables efficient synthesis of chiral alcohols for anticoagulants. Enhanced stability and activity reduce manufacturing costs for pharmaceutical intermediates.
Patent CN110004119B discloses a thermostable epsilon-ketoester reductase mutant enabling efficient synthesis of (R)-alpha-lipoic acid precursors with reduced catalyst loading and enhanced stability.
Patent CN111172124A reveals a novel carbonyl reductase mutant enabling high-concentration synthesis. Discover cost-effective supply chain solutions for this key pharma intermediate.
Patent CN106701698B reveals high-efficiency SsCR enzyme for chiral alcohol synthesis. Achieves 99.9% ee and 500mmol/L substrate concentration for scalable manufacturing.
Patent CN104860980A introduces enzymatic synthesis with high optical purity and mild conditions, enabling cost reduction and reliable supply for pharmaceutical manufacturing.